Novo Nordisk A/S Sponsored ADR (NVO)
Here's 80 Billion More Reasons to Buy Novo Nordisk Stock
Novo Nordisk is already developing its next set of weight loss therapies. At least one market research firm is incredibly optimistic about its prospects.
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market
Democratic U.S. Senate aides will meet with Novo Nordisk executives on Tuesday to discuss fallout from its decision to stop selling one of its long-acting insulins in the country, two sources familiar with the meeting told Reuters.
Ozempic linked with lower dementia risk, nicotine use, British study finds
Novo Nordisk's popular diabetes treatment Ozempic could be tied to a lower risk of cognitive problems, according to an observational study published by researchers at Oxford University.
Novo Nordisk Gains as Ozempic Found To Lower Dementia Rates
American depositary receipts (ADRs) of Novo Nordisk (NVO) rose in intraday trading Friday after the release of an Oxford study that showed the Danish company's Ozempic diabetes drug was linked to lower rates of dementia and a range of mental problems.
Study finds Novo Nordisk's Ozempic may reduce dementia
The study looked at semaglutide, the scientific name for Novo Nordisk's NVO, -2.07% NOVO.B, +0.52% Ozempic, with the intent of looking at whether it caused neurological problems. Instead, it found a 48% decline in dementia relative to those who took sitagliptin, Merck's diabetes drug that's known as Januvia.
Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?
Novo Nordisk (NVO) is an excellent stock to retain as share prices continue to rise, driven by the stellar performance of GLP-1 drugs. New investors should look for stock price dips to make an entry.
Novo (NVO) Gets CRL From FDA for Weekly Basal Insulin Icodec
Novo's (NVO) efforts to get approval for once-weekly basal insulin icodec in the United States suffer a setback as the FDA issues a CRL.
US FDA declines to approve Novo Nordisk's weekly insulin
The U.S. Food and Drug Administration has declined to approve Novo Nordisk's weekly insulin in patients with diabetes, the Danish drugmaker said on Wednesday.
US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices
Senator Bernie Sanders on Wednesday expressed confidence that Novo Nordisk can be convinced to cut the U.S. prices of its popular Ozempic and Wegovy used for weight loss by publicly shaming the drugmaker over how much it charges compared to prices in other countries.
Novo Nordisk, Indonesia's Bio Farma sign deal to produce insulin
Danish drugmaker Novo Nordisk has signed a deal with Indonesia's state-owned pharmaceutical company Bio Farma to produce insulin to combat diabetes in the Southeast Asian country, a Bio Farma senior official said on Wednesday.
Novo Nordisk shares take a hit after a report revealed Eli Lilly's better weight loss drug
Shares in Novo Nordisk, maker of the wildly popular obesity drug Wegovy, were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly's own treatment Mounjaro leads to faster and greater weight loss.
Eli Lilly weight-loss drug found more effective than Novo Nordisk's Ozempic
Novo Nordisk (NYSE:NVO) shares fell and Eli Lilly and Co (NYSE:LLY) rose after a study found the US company's weight-loss drug may be more effective. Lilly's tirzepatide, branded as Mounjaro, was pitted against semaglutide, which Novo Nordisk (NYSE:NVO) makes under the Wegovy higher-dose brand for weight loss and Ozempic for type-2 diabetes, though the patients in the trial were all taking Ozempic.
